Mauna Kea Technologies Expands International Adoption of Cellvizio® for Pancreatic Cystic Lesions with Key Hospital Installations in Spain and the United Arab Emirates

PARIS & BOSTON–(BUSINESS WIRE)–Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announces the clinical deployment of Cellvizio® for improved pancreatic cyst characterization at two flagship institutions: Centro Médico Teknon in Barcelona, the first hospital in Spain, and King’s College Hospital London in Dubai, the first hospital in the Middle East and N

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.